Being a mutant in the Marvel universe is usually sold as a cool thing.You get powers. You join a team. You wear a color-coded ...

Such a puzzle since the patient had neither CVD risk factors nor atherosclerotic changes ...

Low baseline ctDNA levels in advanced breast cancer patients predict better response to targeted therapy and longer ...

Allschwil, Switzerland - February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker ...

Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...

As children, we inherit many traits from our parents—our looks, habits, temperament, and even our values. However, inheritance doesn’t stop there. Certain health conditions can also be passed down ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Black Diamond Therapeutics, Inc. is one of ...

HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C.

On January 12, NP-G2-044 (Prilukae), a novel oral fascin inhibitor earned ODD for the treatment of pancreatic cancer. This designation covers the use of the agent as monotherapy and in combination ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.